Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden.

Published in: Journal of medical economics (2023)

Bimekizumab was cost-effective against most available treatments for PsA in Sweden, irrespective of prior TNFi exposure.

Keyphrases